In this episode of the Bench to Bedside podcast, Dr. Roy Jensen is joined by Dr. Tara Lin, principal investigator for the myeloMatch clinical trial at The University of Kansas Cancer Center, and Dr. Jesus Gonzalez Lugo, recently recognized with a National Career Development Award. They revisit the NCI-sponsored, first-of-its-kind national precision medicine trial for acute myeloid leukemia (AML) and share progress since its 2024 launch, including growth to five enrolling treatment protocols with seven more awaiting activation, more than 1,000 patients screened nationwide, and participation across 200+ U.S. sites. Dr. Lin explains how the master screening protocol returns comprehensive diagnostic results in 72 hours, improving treatment matching and access across KU Cancer Center's main campus, community satellites, and network sites. Dr. Lugo discusses outreach efforts to reduce barriers to trial participation, including education for physicians and patients, community partnerships, and Spanish-language media engagement, and both guests reflect on how myeloMatch could help guide use of the many new AML therapies now available.

00:00 Welcome Back to myeloMatch

01:09 Trial Growth and Milestones

02:58 How Precision Matching Works

04:57 Expanding Access Across Regions

06:15 Dr Lugo Award and Outreach

09:04 Future of AML Treatment

11:21 Closing and Resources

Links from this Episode:

· Listen to our first myeloMATCH episode, "MyeloMATCH: The New Front in the Battle Against Leukemia"

· Learn more about myeloMATCH

· Learn more about Dr. Tara Lin

· Learn more about Dr. Jesus Gonzalez Lugo

· Learn more about the Winn Career Development Award

To ensure you get our latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center.